About: Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 2020

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2020 (fr) scientific article published on 01 May 2020 (en) artículu científicu espublizáu en mayu de 2020 (ast) im Mai 2020 veröffentlichter wissenschaftlicher Artikel (de) наукова стаття, опублікована 1 травня 2020 (uk)
publication date	wds:Q94479056-397E38E8-9373-4CA4-B790-07ECA092D98F
publication date	2020-05-01 00:00:00Z (xsd:dateTime)
cites work	wds:Q94479056-008EEF39-2BB0-4DF7-9284-6B5F35E5B70D wds:Q94479056-074CB8AD-B880-4BC3-B8AB-72009907E783 wds:Q94479056-2BCBBE3B-5D89-4025-9BD7-06F209FEECBE wds:Q94479056-4963704E-550D-4090-BDD8-E8D11F5F01AA wds:Q94479056-5643746C-C0FA-4614-8ED3-B2A81195E3ED wds:Q94479056-565E454D-05B6-4AF3-BD92-B46F0AD75218 wds:Q94479056-74AF72EE-D2C5-4098-949F-6ED052F458E1 wds:Q94479056-74EAFD8B-4113-48BB-B5E6-68EA83673F5B wds:Q94479056-78541500-4E5C-43E4-97E5-5C7A38463163 wds:Q94479056-7F9F1683-4121-4D24-BFC0-4D0ED06BBBD0 wds:Q94479056-8D901CE0-3060-4F56-B7FE-5E2180E10C96 wds:Q94479056-95CD05EA-8F9F-40AB-9E45-1CFB6ED94725 wds:Q94479056-B493471D-F1C1-40FC-8BC6-FED405190C6A wds:Q94479056-BCBBE8A1-F5A0-4BF1-9309-B20F1F0A8332 wds:Q94479056-D988F120-A856-4696-BD95-15F5CC4561B2 wds:Q94479056-DADBBCB2-EEE9-4AE9-A172-EA6A7D4F212C wds:Q94479056-DBFBDAEE-3C36-4D39-98F4-45C2A2AD23E3 wds:Q94479056-DBFC7A13-CB95-4266-9CAE-02D05D8108AF wds:Q94479056-FDB63E11-9FC4-4971-90EB-86AD2685CED1
cites work	Revised response criteria for malignant lymphoma. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma CAR T-Cell Therapy: A Microcosm for the Challenges Ahead in Medicare Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation
author name string	wds:Q94479056-02E293E7-2687-4749-B34F-3726FEB18475 wds:Q94479056-0A26EE36-0B4D-461C-8B77-899E80364D15 wds:Q94479056-0F86ADB5-6020-4F7D-A1CD-BC6F73AB19FB wds:Q94479056-112E9A85-3A57-45B6-8EE6-20BB61794D64 wds:Q94479056-134A00BC-BEBF-4CFB-AE4A-1A366D11B5AE wds:Q94479056-2030A1B8-B79C-4C24-BD65-CCEFC389F23F wds:Q94479056-35536395-8681-4014-A1DE-2202DE4F4947 wds:Q94479056-465BC98A-3592-4973-811D-1AB581C19C33 wds:Q94479056-4E74A139-76CE-4003-AC0E-AAEEEAE73A0F wds:Q94479056-696F83BD-87E4-432A-8CAE-3D1065BFA167 wds:Q94479056-7202E5E7-F8B3-4916-B0C0-4804761839B5 wds:Q94479056-78D73AB4-FD23-48FB-8D5C-10B3C85461F7 wds:Q94479056-803C4F48-DA89-4A40-AE59-921D0F85583D wds:Q94479056-86BC7E15-B1F7-4D9A-9D29-B79E7460E481 wds:Q94479056-A11A3520-40EF-4CB1-8EF6-540A6C4C2DEB wds:Q94479056-A778E88F-BE7E-4586-A999-1B1522C33A31 wds:Q94479056-B7C11AF3-D34B-4763-95F5-8B150124F3B9 wds:Q94479056-B8EC4A65-6442-41EF-84D6-6C8C232F76D1 wds:Q94479056-BE93FE71-4181-4F83-B43F-966EC20B5D06 wds:Q94479056-D0BB964B-FF50-450C-8B98-47093517A684 wds:Q94479056-D81E7049-549B-4796-8613-82A65C992246 wds:Q94479056-D824D293-1F16-449F-8FAF-F03322CFD58F wds:Q94479056-ED4005B5-BB11-49DA-A8E4-C47367EB7E2D
author name string	Caterina Stelitano Maurilio Ponzoni Francesco Zaja Alberto Fabbri Alice Di Rocco Renato Zambello Stefano Volpetti Salvatore Perrone Annalisa Arcari Teresa Calimeri Marco Foppoli Chiara Rusconi Eloise Scarano Alessandro Nonis Alessandro Re Maurizio Frezzato Giovanni Bertoldero Daniela De Lorenzo Piera Angelillo Sara Steffanoni Caterina Cecchetti Marianna Sassone Vittoria Tarantino
rdfs:label	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation (en) Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation (nl)
skos:prefLabel	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation (en) Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation (nl)
name	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation (en) Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation (nl)
author	wds:Q94479056-448F6C98-8F78-4D4E-B282-4ACE8DB8C4A8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software